Decitabine

Name: Decitabine
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (91 reviews)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

91 publications

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine has been cited by 91 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2424

PubMed: 33510302 ( click the link to review the publication )

Nat Commun, 2020, 6;11(1):740

PubMed: 32029739 ( click the link to review the publication )

Oncogene, 2020, 11

PubMed: 32393833 ( click the link to review the publication )

PLoS Genet, 2020, 16(11):e1009159

PubMed: 33175846 ( click the link to review the publication )

J Cancer, 2020, 28;11(10):2874-2886

PubMed: 32226505 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

JCI Insight, 2020, 5(11):e137569

PubMed: 32493845 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11396

PubMed: 32647280 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30632-7

PubMed: 33253790 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )
Genet Test Mol Biomarkers, 2020, 24(7):399-408

PubMed: 32551898 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:6665-6677

PubMed: 32801900 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 10.1111/1440-1681.13390

PubMed: 32754907 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3461-3475

PubMed: 32774712 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:282-294

PubMed: 32728616 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007578

PubMed: 30699189 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 218:241-252

PubMed: 30586565 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Dis Markers, 2019, 2019:9175215

PubMed: 31558918 ( click the link to review the publication )

Mol Psychiatry, 2019, 10.1038/s41380-019-0588-9

PubMed: 31745236 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

J Cancer, 2018, 9(16):2807-2816

PubMed: 30123349 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )
J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(9):1030-41

PubMed: 26056145 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	M{C1b2Z2dmO2aX;uJGF{e2G7	M4G1R\|AvPcLizszN	MkK1NlQhcA>?	Mnnve4F1\XJ?	NGPLRnFud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>?	M4n0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN\|A5OjxxYU6=
Eca109	M3v0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf5U2Q{OC53L{KuOU82KM7:TR?=	M{DTVlI1NzR6L{eyJIg>	MWn3ZZRmeg>?	NEPqbVRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109	NX6zd4R4TnWwY4Tpc44hSXO\|YYm=	NXf5V5BuOC53wrFOwG0>	M2m5NFYwOTJxMkSgbC=>	NXy4d5FXf2G2ZYK=	NGLRdFJqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg	NVPuVIQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109	NGrGbZlHfW6ldHnvckBCe3OjeR?=	NGSzPGIxNjYEoN88US=>	NFTkZW0zPCCq	NGSzdld4[XSnch?=	MVrpcohq[mm2czDj[YxtKGmwdnHzbY9v	M2TqNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN\|A5OjxxYU6=
Eca109	NH7rUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rOc\|AvPcLizszN	NX:zWHN1OjRiaB?=	NH2ySlV4[XSnch?=	NV7lTFN[cW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109	Mnf3SpVv[3Srb36gRZN{[Xl?	MV2wMlUwOSEQvF2=	NGHMRVEzPCCq	MlHke4F1\XJ?	MkDP[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>?	M4DoVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN\|A5OjxxYU6=
SW1116	NGnNfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;6ZVAvPS9zL{KvOUDPxE1?	NFnVR5g1QCCq	MYrEUXNQ	NUO5XZJr\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>?	M3LQ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO	M2T4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS3S28xNjVxMT:yM\|Uh\|ryP	NIPzPIU1QCCq	NH:1NXJFVVOR	MlzX[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=>	NGnWPJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O\|QzQDZ:L3G+
SW1116	MV\GeY5kfGmxbjDBd5NigQ>?	MmrhNVAh\|ryP	MVW0PEBp	NYX5OmdvTE2VTx?=	NVjLcYplcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	MnTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO	M4ThNGZ2dmO2aX;uJGF{e2G7	NYXFNWM3OTBizszN	MnHrOFghcA>?	Mnr2SG1UVw>?	NI\STYxqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ?	NWTJVldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116	MmLIRZBweHSxc3nzJGF{e2G7	MmTUNVAh\|ryP	MYG0PEBp	NWjpcXVVTE2VTx?=	NHP2[XNmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM>	NUPhPWJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO	NHfWT5ZCeG:ydH;zbZMhSXO\|YYm=	MVixNEDPxE1?	MX20PEBp	NFLodmJFVVOR	MnfM[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226	MoXURZBweHSxc3nzJGF{e2G7	NYjvOIF1OS9{IN88US=>	MXe0PE84Oi97NjDo	NITsZplFVVOR	NUj2UVdGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2	NGj0c2FCeG:ydH;zbZMhSXO\|YYm=	NUiybFh6OS9{IN88US=>	NVj4WmpbPzJxOU[vNVIxKGh?	MmG2SG1UVw>?	M2rjSolv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NV;mOHZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3	MVvBdI9xfG:\|aYOgRZN{[Xl?	NXvVO3JSOC53L{Gg{txO	MWSyOE81QCCq	M1nNdGROW09?	MVXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NV3JboxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929	NHfZc2VCeG:ydH;zbZMhSXO\|YYm=	M{\5WlEwOiEQvF2=	M3HMRVczNzl4L{GyNEBp	NVyxUI17TE2VTx?=	NFuy[pFqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NXrjPYVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
RPMI-8226	M3jFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTMPFQyNzJizszN	MV:yOE81QC95MjDo	MoCzSG1UVw>?	NEP4SnBi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
OPM-2	NYr1VnVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;GVFEwOiEQvF2=	MkHiNlQwPDhxN{KgbC=>	MWLEUXNQ	NIjwdYRi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	NGDG[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN\|ExQCd-MkS4N\|MyODh:L3G+
JJN3	NXvi[G45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHYeFRsOC53L{Gg{txO	NXvyR\|VOOjRxNEivO\|IhcA>?	M4jR[2ROW09?	NH;3b\|hi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	NX7SU5liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6yW3IyNzJizszN	Mn7ONlQwPDhxN{KgbC=>	MkG1SG1UVw>?	NVrxSYR1[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa	M{XpSGtqdmG\|ZTDBd5NigQ>?				NFrxdWJMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy	NG\CZVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa	M4jl[2tqdmG\|ZTDBd5NigQ>?				NFm4bGdMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI>	NFr6U\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa	NYr1fGNpU2mwYYPlJGF{e2G7				NW\5VmVCU2l;MkGuOkDDuSB\|LkCg{txOKG[xcjDoR25VOQ>?	M{HCW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa	M4\3WGtqdmG\|ZTDBd5NigQ>?				MkjpT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=>	Ml;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
NB4	NYDlTphGTnWwY4Tpc44hSXO\|YYm=	M4PzOVIvPS93L{euOU8yOCEQvF2=	NGLCXFAzPCCq	M3;vfWROW09?	NHOyRoFqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NEi3NEc,OjR2OES4O\|A9N2F-
CD4+ CD25− T	MknRSpVv[3Srb36gRZN{[Xl?	MXixM\|Uh\|ryP			M2HJUJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	NVnROGRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|Y{PjBpPkK0OFc3OzZyPD;hQi=>
BV-173	MmjKRZBweHSxc3nzJGF{e2G7	MUOwMlI2NzBwNT:wMlc2NzFizszN	NUC0R\|NSPDhxN{KvPVYhcA>?	NX[2WpNZyqCSQmO=	MlnQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	NI\4UJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
ML-1	M1uwWmFxd3C2b4Ppd{BCe3OjeR?=	Mm\nNE4zPS9yLkWvNE44PS9zIN88US=>	NVK4dY5ZPDhxN{KvPVYhcA>?	MojixsBRSlN?	NIrhXZVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NYjWXVE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HL-60	M{i5dGFxd3C2b4Ppd{BCe3OjeR?=	NWTvcW1FOC5{NT:wMlUwOC55NT:xJO69VQ>?	NIjvdoM1QC95Mj:5OkBp	M1vpeeKhWEKV	NIXibpVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	M{fTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
KG-1a	MkLKRZBweHSxc3nzJGF{e2G7	MYmwMlI2NzBwNT:wMlc2NzFizszN	NIK2SGU1QC95Mj:5OkBp	M{TLW:KhWEKV	NIfUfpBqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NEjqUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
BV-173	NXe5bpFXTnWwY4Tpc44hSXO\|YYm=	MnLQNlUxNzVyMH7N	M{LPcVQ5KGh?	M1XWOOKhWEKV	M1Lw[Ylv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	M1;K[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
CEM	M{TpZ2Z2dmO2aX;uJGF{e2G7	MknBNlUxNzVyMH7N	NX7GWoUxPDhiaB?=	NWnVN3dXyqCSQmO=	M{XvWIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	M1LJclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
HL-60	M2HFZ2Z2dmO2aX;uJGF{e2G7	MnnMNlUxNzVyMH7N	MYe0PEBp	MXZCpHBDWw>?	MVfpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	M{fnOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
ML-1	MojLSpVv[3Srb36gRZN{[Xl?	MWeyOVAwPTBybl2=	NXLXbWJDPDhiaB?=	MWlCpHBDWw>?	NXHVcYFRcW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	M17LfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
DLD-1	Mnq1SpVv[3Srb36gRZN{[Xl?	NGO0PFIzPTBxNUCwcm0>	NELrUVM1QCCq	MWRCpHBDWw>?	MWrkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	NUjsXYczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HCT-116	M13oOmZ2dmO2aX;uJGF{e2G7	Mmn0NlUxNzVyMH7N	NV7ic2M{PDhiaB?=	MkfqxsBRSlN?	NH6zZWxldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18	MkfQRZBweHSxc3nzJGF{e2G7	MWWwMlAyNzBwMT:xM\|ExKM7:TR?=	NWPwWHZbPDhiaB?=		NWDENmdrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXn3d4d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N\|AxPDV4PD;hQi=>
HT29	NI\ycIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{\rVVczKGh?		MXvJR\|UxRTF2MEFCtVE4QSEQvF2=	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnXRO\|IhcA>?		NGC3UHJKSzVyPUG1MlLDuTZwMjFOwG0>	M1\ueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
HCT116	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NULu[5B7PzJiaB?=		MXrJR\|UxRTFwN9MxNE41KM7:TR?=	NHvhUHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO\|IxPjF:L3G+
HepG2	NUX6O5hITnWwY4Tpc44hSXO\|YYm=	MV[wMlUwOSEQvF2=	MU[yOEBp	M4PVU2ROW09?	NVj4dWZNfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	NEG5V2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
LS174T	MVrGeY5kfGmxbjDBd5NigQ>?	MmDmNE42NzFizszN	M2DjNFI1KGh?	M1;DWGROW09?	NF3zS5Bt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=>	NE\QcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
HepG2	NUTFc29HSXCxcITvd4l{KEG\|c3H5	NVHZZ\|NLOS9zMD:xNFAh\|ryP	MWq3JIQ>	NH\vXVJFVVOR	NH7NRXVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
LS174T	NILKbFlCeG:ydH;zbZMhSXO\|YYm=	MmrkNU8yOC9zMECg{txO	NWX2VJdZPyCm	NIi2SWdFVVOR	MVvpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
QBC-939	MnjVRZBweHSxc3nzJGF{e2G7	NEDTOYcyNzFyL{GwNEDPxE1?	MXK3JIQ>	NVLyOVVwTE2VTx?=	MnTYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M32zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
U251	NF7uWIRCeG:ydH;zbZMhSXO\|YYm=	NXHPVo9wOS9zMD:xNFAh\|ryP	MUW3JIQ>	NXTh[Yo6TE2VTx?=	MUjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NX3oZYE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HL-60	NG\DV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxJO69VQ>?	NYHvTlA3PDhiaB?=		NV7rZYM3cW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36=	NIDkZWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwNFMzPCd-MkSwNFA{OjR:L3G+
MDA‑MB‑453	MXrGeY5kfGmxbjDBd5NigQ>?	MoDqNE4zNzFizszN	MYq3NkBp		NE\3V2Jk[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ\|OES0NlI5RC:jPh?=
HCC1569	Mn;uSpVv[3Srb36gRZN{[Xl?	NGHjZncxNjJxMTFOwG0>	NUjrVlc5PzJiaB?=		M{LPToNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	NULqbmtMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
BT‑474	MXHGeY5kfGmxbjDBd5NigQ>?	M{[1SFAvOi9zIN88US=>	NIO5OZc4OiCq		NFLGUY9k[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	M32yNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS	NYTTPZdNSXCxcITvd4l{KEG\|c3H5	NF23SYg2NzFyL{KwM\|UxKM7:TR?=	MXe0POKhcMLi	NHHabmpFVVOR	MnT0bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA>	NUftPIt6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
A549	MVrBdI9xfG:\|aYOgRZN{[Xl?	NUXGc3Q{PS9zMD:yNE82OCEQvF2=	M2\ldlQ5yqCqwrC=	M2\ETWROW09?	MVTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	NGrOfIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
AGS	NFrSempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXmOU8yOC9{MD:1NEDPxE1?	MnryOFjDqGkEoB?=	MmLHSG1UVw>?	NF\Ie5ZqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA>	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ\|NUiyO\|g1RC:jPh?=
Kasumi-1	MnflRZBweHSxc3nzJGF{e2G7	MnTJNE42KM7:TR?=	MYC0POKhcMLi		MYHk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2\|Yx?=	NWDoVYNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
OCI-AML3	NXvnVXFUSXCxcITvd4l{KEG\|c3H5	MWGyMlUh\|ryP	NFvn[5E1QMLiaNMg		NW\xXYxW\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ\|NEmzN\|Q5RC:jPh?=
MV4-11	MmDFRZBweHSxc3nzJGF{e2G7	M2K4R\|IvPSEQvF2=	NXLTZXVzPDkEoHlCpC=>		MUHk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2\|Yx?=	M1jhXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzN\|Q5Lz5{M{S5N\|M1QDxxYU6=
NK	M2\xXWN6fG:2b4jpeJkhSXO\|YYm=	MmTsNE4xOi1{MDFOwG0>	M3;oOVUh\A>?		MV;k[YNz\WG\|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW\|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN\|MkiwPFg9N2F-
NK	MX3BdI9xfG:\|aYOgRZN{[Xl?	NEnDbHMxNjB{LUKwJO69VQ>?	MmfpOUBl		NWrKV\|Bn\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm	NHjNW449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK	NVS5XHhrTnWwY4Tpc44hSXO\|YYm=	NH;wcZoxNjBzLUKwJO69VQ>?	MXO1JIQ>		MkPvZ4F2e2W\|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=>	M3fnfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
MOLT4/DNR	NV7DUJE4TnWwY4Tpc44hSXO\|YYm=	MYe1JO69VQ>?	M{LNZlQh\A>?		M2jmUpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v	Mk\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O\|AoRjJ\|ME[wOVcxRC:jPh?=
Jurkat/DOX	M1L4XGZ2dmO2aX;uJGF{e2G7	M{e0clUh\|ryP	M4XHdlQh\A>?		MnL0doVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	M3\QR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\xdFFkPSEQvF2=	MmPpOEBl		M3Oz[JJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm=	MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O\|AoRjJ\|ME[wOVcxRC:jPh?=
Jurkat/DOX	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\4eZE2KM7:TR?=	NXLrRVY{PCCm		NGXqbG1z\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5	M{LV[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC	NYr1cJVlSXCxcITvd4l{KEG\|c3H5	Mmi2NE4xOS1zMN88US=>	M3PzeVczKGh?	M2jmV2ROW09?	M1Pz[IhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25?	NH7XRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC	M2rZSGFxd3C2b4Ppd{BCe3OjeR?=	MkP1NE4xOS1zMN88US=>	NVm4UY93PzJiaB?=	M2Dp[WROW09?	MVLoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	NFL1U5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
A498	NES3b5FCeG:ydH;zbZMhSXO\|YYm=	MnPkNE4xOS1zMN88US=>	M1vSSlczKGh?	MUDEUXNQ	MmjYbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	NHnaWIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
KIJ265T	NFviO3RCeG:ydH;zbZMhSXO\|YYm=	MVSwMlAyNTFyzszN	NUW4eXBMPzJiaB?=	MUTEUXNQ	MmPGbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
MDA-231	NYmxVFJzSXCxcITvd4l{KEG\|c3H5	MX[wMlAyNTFyzszN	Mn7jO\|IhcA>?	MoDUSG1UVw>?	NGHzU29qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
BT-20	Ml\sRZBweHSxc3nzJGF{e2G7	NV7jVXUyOC5yMT2xNO69VQ>?	MWe3NkBp	MXjEUXNQ	M3zEUYlv\HWlZYOgd5lv\XKpaYP0bYMhemW\|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4>	NXf5XHVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nLSVUuOjBizszN	MmDsNlQwPDhxN{KgbC=>		M4r5TIlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUOwcZczPS1{MDFOwG0>	NEGxZpMzPC92OD:3NkBp		NUfzXpFkcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
U937	MVTBdI9xfG:\|aYOgRZN{[Xl?	NITibZEyPSEQvF2=	Mo[5NlQwPDhxN{KgbC=>		M3vYN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NW\LXoI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO\|Y4ODJzPD;hQi=>
HL60	M16wRmFxd3C2b4Ppd{BCe3OjeR?=	NWLac5ZtOTVizszN	NFLuNo0zPC92OD:3NkBp		MV;pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3G2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O\|AzOTxxYU6=
LS411N	NVfHW3p[SXCxcITvd4l{KEG\|c3H5	MWiwMlUh\|ryP	MojkO\|IhcA>?		NGHISmtqdmO{ZXHz[ZMhTmG\|IH3SUmEhdGW4ZXy=	NYSxV41ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlE3QTVpPkKyOFYyPjl3PD;hQi=>
MDA-MB-231	MYDBdI9xfG:\|aYOgRZN{[Xl?	NYHhSHlsOTBizszN	NXLocG9uPDhiaB?=		M3HNUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
MCF-7	NIjFOWFCeG:ydH;zbZMhSXO\|YYm=	NH;tN5kyOCEQvF2=	NUHCRnA{PDhiaB?=		M33yT5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYPiWYhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
A375	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViwMlUh\|ryP	MUexM\|UwQCCm		MYrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	M{L3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL1	M4m5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\2TVAvPSEQvF2=	NF;BXmMyNzVxODDk		NHzIcYZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?=	MlS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL3	NVfz[IxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnZNE42KM7:TR?=	MofFNU82NzhiZB?=		M3rxd4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28	M2nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfHO2E1OC53IN88US=>	MlfDNU82NzhiZB?=		MkCxbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
MeWo	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDsNE42KM7:TR?=	Mn\6NU82NzhiZB?=		MUHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
B16	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13wU\|AvPSEQvF2=	MnSzNU82NzhiZB?=		MXjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	M2HaRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
Ly 1	NVXi[oxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF;LTI0zPCCq		MV7JR\|UxRTdwMzFOwG0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;HPVI1KGh?		M4XkWGlEPTB;MUCuO{DPxE1?	MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6	M1y5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn7rNlQhcA>?		NGToOGpKSzVy78{eNlAh\|ryP	NGDoTFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
Ly 10	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkDBNlQhcA>?		NHPPRnlKSzVy78{eNlAh\|ryP	M1zxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYjp[WhlOjRiaB?=		M1nGS2lEPTExvK6yNEDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	M{LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIiyO24zPCCq		MmjkTWM2OO,:nkKwJO69VQ>?	MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1	NYDHfVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGTYN3M1QCCq		NEC5NppKSzVyPUCuN\|Qh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7	NHnCb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH7pXVM1QCCq		NYnQ[ZJUUUN3ME2wMlAzPSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVjGTXUyPDhiaB?=		NVvWUVVEUUN3MP-8olIxKM7:TR?=	MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10	M1uze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1T5XVQ5KGh?		NGj6VlVKSzVyPUGuPEDPxE1?	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA	M3rwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mon5OFghcA>?		M1HyU2lEPTExvK6yNEDPxE1?	M3\sUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2	NV7pelljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVS0PEBp		MUHJR\|UxRTF5LkSg{txO	NVvKbI9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 1	NX;SdZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoT1O\|IhcA>?		NUnXZpJ1UUN3ME2wMlAyKM7:TR?=	Mo\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfpcYY4OiCq		NVrkOYJQUUN3ME2wMlAyQCEQvF2=	M{PiPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mni3O\|IhcA>?		NGXZOXBKSzVyPUGuOkDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 10	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XWfFczKGh?		MoPwTWM2OD1zLkKg{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
RIVA	NYj4fVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn31O\|IhcA>?		M{TwcmlEPTExvK6yNEDPxE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	NUPkfXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHmwWmo4OiCq		NHLRPIFKSzVyPUGxMlIh\|ryP	MoXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
U373-MAGI	M2S2XGFvfGm4aYLhcEBie3OjeR?=	M3jvWlAvOjVidH:gPEB2VQ>?	M1fZTlIhfG9iN{KgbJJ{		NX\T[G5zSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNE4zPSC2bzC4JJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k	M2TsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	M4PtXGFvfGm4aYLhcEBie3OjeR?=	MoXMNE4zPSC2bzC4JJVO	NF\yeHIzKHSxIEeyJIhzew>?		M17wSWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV\|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDBwMkWgeI8hQCC3TTDh[pRmeiB{IITvJFczKGi{czDifUByWEOUIH3leIhw\A>?	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 8 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals Inc.	April 17 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine